Cinclus Pharma Holding AB (publ) (STO:CINPHA)

Sweden flag Sweden · Delayed Price · Currency is SEK
16.08
+0.34 (2.16%)
At close: Jul 8, 2025
-52.00%
Market Cap 739.95M
Revenue (ttm) 4.58M
Net Income (ttm) -164.81M
Shares Out 46.54M
EPS (ttm) -3.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,634
Average Volume 71,115
Open 15.70
Previous Close 15.74
Day's Range 15.70 - 16.26
52-Week Range 9.31 - 35.30
Beta n/a
RSI 54.83
Earnings Date Aug 20, 2025

About Cinclus Pharma Holding AB

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and... [Read more]

Sector Healthcare
Founded 2014
Employees 18
Stock Exchange Nasdaq Stockholm
Ticker Symbol CINPHA
Full Company Profile

Financial Performance

In 2024, Cinclus Pharma Holding AB's revenue was 4.58 million, a decrease of -23.14% compared to the previous year's 5.96 million. Losses were -168.03 million, -21.89% less than in 2023.

Financial Statements

News

There is no news available yet.